Cost-minimization analysis of HYQVIA® in the treatment of primary immunodeficiency disease (PID) and secondary immunodeficiency disease (SID) in Italy

Authors: Roberto Ravasio, Silvia Ripoli

Source: AboutOpen, Vol 10, Iss 1 (2023)

Subject Terms: Cost, HYQVIA®, Immunoglobulin, Primary immunodeficiency disease, Secondary immunodeficiency disease, Medicine

File Description: electronic resource

Relation: https://journals.aboutscience.eu/index.php/aboutopen/article/view/2584; https://doaj.org/toc/2465-2628

Access URL: https://doaj.org/article/3ba17007ad4b4ff793f2f736c0656323

Non-interventional post-marketing safety study on the long-term safety of HyQvia (global)

Authors: Lina Laguado, Katharina Fielhauer, Andras Nagy, Christopher J. Rabbat, Barbara McCoy, Heinz Leibl, Leman Yel

Source: Revista Alergia México, Vol 65 suppl 1, p 133 (2018)

Subject Terms: post-marketing safety, recombinant human hyaluronidase-facilitated subcutaneous infusion of igg, hyqvia, Immunologic diseases. Allergy, RC581-607

File Description: electronic resource

Relation: http://revistaalergia.mx/ojs/index.php/ram/article/view/501; https://doaj.org/toc/0002-5151; https://doaj.org/toc/2448-9190

Access URL: https://doaj.org/article/0f6a7cf061704ddab81e8c5d4042af84

The Future of Chronic Inflammatory Demyelinating Polyneuropathy Treatment With the FDA Approval of Hyqvia: Richard Lewis, MD

Authors: By:Richard Lewis, MD

Source: Neurology Live (USA), January 21, 2024 News, 3pp

FDA Approves HyQvia as Maintenance Therapy for Rare Neuromuscular Disorder

Authors: By:Formulary Watch

Source: Formulary Watch (USA), January 17, 2024 News, 2pp

FDA Approves Takeda's Immune Globulin Infusion, Hyqvia, for Chronic Inflammatory Demyelinating Polyneuropathy

Authors: By:Isabella Ciccone, MPH

Source: Neurology Live (USA), January 16, 2024 News, 5pp

Takeda receives positive CHMP opinion for HYQVIA as maintenance therapy in patients with chronic inflammatory demyelinating polyneuropathy (CIDP).

Source: Chemical Business NewsBase (UK), December 15, 2023, 2pp

After a 6-month courtship, Baxalta (BXLT) finally says yes to $32 bn Shire (SHPG) marriage proposal.

Source: Chemical Business NewsBase (UK), January 11, 2016, 2pp

About 500 Kendall Square Baxalta (BXLT) staffers in limbo as Shire (SHPG) merger talks drag on.

Source: Chemical Business NewsBase (UK), May 19, 2016, 1pp

Shire (SHPG) not spooked by Pfallergan breakup, remains committed to Baxalta (BXLT).

Source: Chemical Business NewsBase (UK), April 7, 2016, 2pp

FDA approves Baxter International Inc (BAX), Halozyme Therapeutics Inc (HALO)'s Hyqvia.

Source: Chemical Business NewsBase (UK), September 15, 2014, 1pp